Market reports & researches
LOG IN | Services | Contact | Custom Research



Main Healthcare, Pharmaceuticals & Biotechnology Healthcare and drugs U.S. Stroke Therapies Markets
Publications

(Currently 512486 Items)


Partners


Healthcare and drugs / REPORT INFORMATION

U.S. Stroke Therapies Markets

DateMay, 2001
Pages0
Price / format€4106 / Hard Copy
€3729 / Site License
€4859 / Enterprisewide

€3 699 

Report Information | Custom-Tailored Research | Product Trade Lead


Abstract:


Already a leading cause of death, stroke cases are expected to double during

the next half century. Consequently, the markets for stroke therapies offer

important opportunities for companies that can overcome research

challenges. Market participants must continue to research new classes of

drugs, combinations of agents, and alternate treatments in what may seem to

be a never-ending search for effective treatment.


This compelling Frost & Sullivan study analyzes the markets for stroke

therapies and examines current research activities for therapeutics. Following

an overview of the disease's risk factors, symptoms, tests, and treatments, this

report evaluates market drivers, restraints, and challenges. With its detailed

discussions of emerging products and its expert forecasts, this report offers

key insights into the future of a growing industry.


Increasing Public and Physician Awareness Key to Market Growth


There is currently a lack of knowledge regarding stroke symptoms and how

to react if someone develops these symptoms, writes the research's author.

The development thrombolytic agents for stroke means that fast diagnosis and

treatment can stop artery blockage in the brain, sparing nerves and saving

related physical functions. Unfortunately, the public perception that stroke is

untreatable often prevents stroke victims from receiving prompt care.


Pharmaceutical companies also must devote resources to educating healthcare

providers as to identifying eligible patients and administering drugs within the

appropriate time frame. This report, which surveys recent medical studies and

assesses their implications for the marketplace, is an essential tool for

industry participants.


Continued Investments In Research and Development Crucial For Success


Many drugs that were thought to be great drug candidates in the early stage

have produced disappointing results in late clinical trial stages, says the

author. A glycine antagonist was promising in early research but ultimately

showed disappointing results. An opoid antagonist appeared to be safe and

well tolerated but failed to yield treatment benefits in patients treated within

six hours.


Many companies are wary of conducting research in this area for fear of

encountering failure and wasting resources. Nevertheless, the demand for

new and effective therapies will not diminish. Companies that persevere and

focus their energies in the key research and development areas will realize

impressive gains. By targeting recent accomplishments and analyzing failures,

this report can help set your firm on the road to success.











Table of contents:
 - Executive Summary

- Market Overview

- Major Research Findings

- Total Market

- Overview and Definitions

- Market Dynamics

- Forecasts and Trends

- Competitive Analysis

- Strategic Recommendations

- Market Engineering Awards

- Research Activities in Stroke Therapeutics

- Overview and Scope

- Emerging Products

- Companies

- Research Methodology

- List of Abbreviations

- Glossary of Terms

- Table of Figures

- Table of Charts




Order this report

  Company name:
  Contact person:
  Phone/fax:
  Email:
  Comments:
   


Product Trade Lead
0 leads found


Add New Buy/Sell Lead

© 2007-2010 MarketReportFinder.com